Very high uptake of risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers: A single-center experience

Gynecologic Oncology

Volumn 143, Issue 1, 2016, Pages 113-119

  Harmsen, M G ^a   Arts de Jong, M ^a   Horstik, K ^a   Manders, P ^a   Massuger, L F A G ^a   Hermens, R P M G ^a   Hoogerbrugge, N ^a   Woldringh, G H ^a   de Hullu, J A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; AGE; AGED; ARTICLE; COHORT ANALYSIS; FEMALE; GENE MUTATION; HEALTH CARE UTILIZATION; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; NETHERLANDS; OVARY CARCINOMA; PRIORITY JOURNAL; PROPHYLACTIC SURGICAL PROCEDURE; RETROSPECTIVE STUDY; RISK REDUCTION; SALPINGOOOPHORECTOMY; TERTIARY CARE CENTER; TIME TO TREATMENT; VERY ELDERLY; ADOLESCENT; GENETICS; MUTATION; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; OVARIECTOMY; SALPINGECTOMY; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; AGED; FEMALE; GENES, BRCA1; GENES, BRCA2; HETEROZYGOTE; HUMANS; MIDDLE AGED; MUTATION; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; OVARIECTOMY; RETROSPECTIVE STUDIES; RISK REDUCTION BEHAVIOR; SALPINGECTOMY;

EID: 84990191659     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2016.07.104     Document Type: Article

References (36)

1. [1] Chen, S., Parmigiani, G., Meta-analysis of BRCA1 and BRCA2 penetrance. J. Clin. Oncol. 25 (2007), 1329–1333.
2. [2] Hermsen, B.B., Olivier, R.I., Verheijen, R.H., van Beurden, M., de Hullu, J.A., Massuger, L.F., et al. No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study. Br. J. Cancer 96 (2007), 1335–1342.
3. [3] Rebbeck, T.R., Kauff, N.D., Domchek, S.M., Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J. Natl. Cancer Inst. 101 (2009), 80–87.
4. [4] Marchetti, C., De Felice, F., Palaia, I., Perniola, G., Musella, A., Musio, D., et al. Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers. BMC Womens Health, 14, 2014, 150.
5. [5] Antoniou, A., Pharoah, P.D., Narod, S., Risch, H.A., Eyfjord, J.E., Hopper, J.L., et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am. J. Hum. Genet. 72 (2003), 1117–1130.
6. [6] Guidelines, N.C.C.N., Genetic/Familial High-Risk Assessment: Breast and Ovarian. 1.2015 Ed. 2015, National Comprehensive Cancer Network, Washington, PA.
7. [7] Walker, J.L., Powell, C.B., Chen, L.M., Carter, J., BaeJump, V.L., Parker, L.P., et al. Society of gynecologic oncology recommendations for the prevention of ovarian cancer. Cancer, 2015.
8. [8] Erfelijke tumoren: Richtlijnen voor diagnostiek en preventie. Vierde druk: Stichting Opsporing Erfelijke tumoren en Vereniging Klinische Genetica Nederland, Werkgroep Klinische Oncogenetica. 2010.
9. [9] Hartmann, L.C., Lindor, N.M., The role of risk-reducing surgery in hereditary breast and ovarian cancer. N. Engl. J. Med. 374 (2016), 454–468.
10. [10] Howard, A.F., Balneaves, L.G., Bottorff, J.L., Women's decision making about risk-reducing strategies in the context of hereditary breast and ovarian cancer: a systematic review. J. Genet. Couns. 18 (2009), 578–597.
11. [11] De Leeuw, J.R., van Vliet, M.J., Ausems, M.G., Predictors of choosing life-long screening or prophylactic surgery in women at high and moderate risk for breast and ovarian cancer. Familial Cancer 7 (2008), 347–359.
12. [12] Miller, S.M., Roussi, P., Daly, M.B., Scarpato, J., New strategies in ovarian cancer: uptake and experience of women at high risk of ovarian cancer who are considering risk-reducing salpingo-oophorectomy. Clin. Cancer Res. 16 (2010), 5094–5106.
13. [13] Beattie, M.S., Crawford, B., Lin, F., Vittinghoff, E., Ziegler, J., Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers. Genet. Test. Mol. Biomark. 13 (2009), 51–56.
14. [14] Sidon, L., Ingham, S., Clancy, T., Clayton, R., Clarke, A., Jones, E.A., et al. Uptake of risk-reducing salpingo-oophorectomy in women carrying a BRCA1 or BRCA2 mutation: evidence for lower uptake in women affected by breast cancer and older women. Br. J. Cancer 106 (2012), 775–779.
15. [15] Kim, S.I., Lim, M.C., Lee, D.O., Kong, S.Y., Seo, S.S., Kang, S., et al. Uptake of risk-reducing salpingo-oophorectomy among female BRCA mutation carriers: experience at the National Cancer Center of Korea. J. Cancer Res. Clin. Oncol. 142 (2016), 333–340.
16. [16] Pal, T., Lee, J.H., Besharat, A., Thompson, Z., Monteiro, A.N., Phelan, C., et al. Modes of delivery of genetic testing services and the uptake of cancer risk management strategies in BRCA1 and BRCA2 carriers. Clin. Genet. 85 (2014), 49–53.
17. [17] Bradbury, A.R., Ibe, C.N., Dignam, J.J., Cummings, S.A., Verp, M., White, M.A., et al. Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers. Genet. Med. 10 (2008), 161–166.
18. [18] Manchanda, R., Burnell, M., Abdelraheim, A., Johnson, M., Sharma, A., Benjamin, E., et al. Factors influencing uptake and timing of risk reducing salpingo-oophorectomy in women at risk of familial ovarian cancer: a competing risk time to event analysis. BJOG 119 (2012), 527–536.
19. [19] van Driel, C.M., de Bock, G.H., Arts, H.J., Sie, A.S., Hollema, H., Oosterwijk, J.C., et al. Stopping ovarian cancer screening in BRCA1/2 mutation carriers: effects on risk management decisions & outcome of risk-reducing salpingo-oophorectomy specimens. Maturitas 80 (2015), 318–322.
20. [20] van der Aa, J.E., Hoogendam, J.P., Butter, E.S., Ausems, M.G., Verheijen, R.H., Zweemer, R.P., The effect of personal medical history and family history of cancer on the uptake of risk-reducing salpingo-oophorectomy. Familial Cancer 14 (2015), 539–544.
21. [21] Madalinska, J.B., van Beurden, M., Bleiker, E.M., Valdimarsdottir, H.B., Lubsen-Brandsma, L., Massuger, L.F., et al. Predictors of prophylactic bilateral salpingo-oophorectomy compared with gynecologic screening use in BRCA1/2 mutation carriers. J. Clin. Oncol. 25 (2007), 301–307.
22. [22] Meijers-Heijboer, H., Brekelmans, C.T., Menke-Pluymers, M., Seynaeve, C., Baalbergen, A., Burger, C., et al. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation. J. Clin. Oncol. 21 (2003), 1675–1681.
23. [23] Dhar, S.U., Cooper, H.P., Wang, T., Parks, B., Staggs, S.A., Hilsenbeck, S., et al. Significant differences among physician specialties in management recommendations of BRCA1 mutation carriers. Breast Cancer Res. Treat. 129 (2011), 221–227.
24. [24] Den Heijer, M., van Asperen, C.J., Harris, H., Nippert, I., Schmidtke, J., Bouhnik, A.D., et al. International variation in physicians’ attitudes towards prophylactic mastectomy — comparison between France, Germany, The Netherlands and the United Kingdom. Eur. J. Cancer 49 (2013), 2798–2805.
25. [25] Julian-Reynier, C., Eisinger, F., Moatti, J.P., Sobol, H., Physicians’ attitudes towards mammography and prophylactic surgery for hereditary breast/ovarian cancer risk and subsequently published guidelines. Eur. J. Hum. Genet. EJHG. 8 (2000), 204–208.
26. [26] Julian-Reynier, C.M., Bouchard, L.J., Evans, D.G., Eisinger, F.A., Foulkes, W.D., Kerr, B., et al. Women's attitudes toward preventive strategies for hereditary breast or ovarian carcinoma differ from one country to another: differences among English, French, and Canadian women. Cancer 92 (2001), 959–968.
27. [27] Evans, D.G., Lalloo, F., Ashcroft, L., Shenton, A., Clancy, T., Baildam, A.D., et al. Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent. Cancer Epidemiol. Biomark. Prev. 18 (2009), 2318–2324.
28. [28] Metcalfe, K.A., Birenbaum-Carmeli, D., Lubinski, J., Gronwald, J., Lynch, H., Moller, P., et al. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int. J. Cancer 122 (2008), 2017–2022.
29. [29] Friebel, T.M., Domchek, S.M., Neuhausen, S.L., Wagner, T., Evans, D.G., Isaacs, C., et al. Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers. Clin. Breast Cancer 7 (2007), 875–882.
30. [30] Laitman, Y., Vaisman, Y., Feldman, D., Helpman, L., Gitly, M., Paluch Shimon, S., et al. Rates of risk-reducing surgery in Israeli BRCA1 and BRCA2 mutation carriers. Clin. Genet. 85 (2014), 68–71.
31. [31] This, P., de la Rochefordiere, A., Savignoni, A., Falcou, M.C., Tardivon, A., Thibault, F., et al. Breast and ovarian cancer risk management in a French cohort of 158 women carrying a BRCA1 or BRCA2 germline mutation: patient choices and outcome. Familial Cancer 11 (2012), 473–482.
32. [32] Heemskerk-Gerritsen, B.A., Seynaeve, C., van Asperen, C.J., Ausems, M.G., Collee, J.M., van Doorn, H.C., et al. Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction. J. Natl. Cancer Inst., 107, 2015.
33. [33] Eisinger, F., Geller, G., Burke, W., Holtzman, N.A., Cultural basis for differences between US and French clinical recommendations for women at increased risk of breast and ovarian cancer. Lancet 353 (1999), 919–920.
34. [34] Skytte, A.B., Gerdes, A.M., Andersen, M.K., Sunde, L., Brondum-Nielsen, K., Waldstrom, M., et al. Risk-reducing mastectomy and salpingo-oophorectomy in unaffected BRCA mutation carriers: uptake and timing. Clin. Genet. 77 (2010), 342–349.
35. [35] Heemskerk-Gerritsen, B.A., Menke-Pluijmers, M.B., Jager, A., Tilanus-Linthorst, M.M., Koppert, L.B., Obdeijn, I.M., et al. Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis. Ann. Oncol. 24 (2013), 2029–2035.
36. [36] Harmsen, M.G., Arts-de Jong, M., Hoogerbrugge, N., Maas, A.H., Prins, J.B., Bulten, J., et al. Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study. BMC Cancer, 15, 2015, 593.